Erasmus MC Biomedical Fund

To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.

To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.

To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.

Cavadis is a Dutch biomedical company focused on cardiovascular risk assessment. It specializes in developing prognostic tests aimed at identifying patients at risk for cardiovascular diseases, including heart attacks and strokes. By discovering novel biomarkers that are more predictive of cardiovascular events than traditional risk factors, Cavadis enables healthcare professionals to personalize treatment plans. The company aims to create clinically meaningful risk stratification tools that enhance patient outcomes through tailored interventions.

Therosteon is a new biotech fledgling emerging from the Erasmus Medical Center in Rotterdam (The Netherlands). The Company develops novel therapeutics for bone diseases including osteoporosis, osteoarthritis, and bone metastasis based on its OsteoBLAST technology platform. Bone diseases represent an interesting market opportunity, with huge unmet medical needs. Osteoporosis in itself represents a huge market opportunity with drug sales totaling 7 billion. Therosteon is located in incubator facilities of the Erasmus MC and collaborates closely with academic group of its scientific founder Prof. Hans van Leeuwen.

RiverD International B.V. specializes in innovative solutions for healthcare and life sciences research, focusing on the application of Raman spectroscopy. Their instruments enable the analysis of both vivo and ex vivo tissues, providing detailed characterization of skin at a molecular level. This technology allows for the non-invasive assessment of personal care products and pharmaceuticals, facilitating the determination of the concentration and distribution of key components such as amino acids, lipids, proteins, and water. By leveraging Raman spectroscopy, RiverD empowers clinicians with critical information necessary for evaluating the effectiveness of topically applied materials and enhancing treatment outcomes.